Services >> Cell Based Phenotypic >> Anti-Infectives

In vitro phenotypic – anti-infectives

Sidebar Image
undefined

In vitro services to find the next generation drugs to combat infectious disease

With the rising prevalence of drug-resistant microorganisms, effective and potent anti-infective agents are becoming increasingly more relevant in order to treat infectious diseases. Eurofins, through the expertise of Panlabs, identified this need over 25 years ago and has since been working diligently with the pharmaceutical industry to provide a robust portfolio of in vitro and in vivo anti-infective models to support the discovery and development of novel antimicrobial therapies.

Our in vitro portfolio follows the standard industry methods (CLSI) in order to evaluate the antimicrobial activity of your test agents. Our services have unmatched flexibility, allowing for combination testing, determining synergistic, indifferent, or antagonistic effects as well as resistance analysis to determine the rate at which organisms develop a non-susceptible phenotype which can have major clinical implications.

Using a comprehensive collection of over 270 clinically relevant Gram-positive and -negative bacteria (including multi-drug resistant, MDR, organisms), anaerobic bacteria, yeast, and filamentous fungi, Eurofins provides the support and experience that your anti-infective drug program needs to succeed.

Features of in vitro anti-infective services from Eurofins:

    • Determination of minimum inhibitory concentration (MIC)
      • Minimum Bactericidal Concentration (MBC)
      • Antibiotic susceptible organisms
      • MDR organisms, clinically relevant resistant mechanisms
      • Effect of human and/or mouse serum
      • Accelerated, one-week turnaround time is available
      • High volume compound testing
    • Panels for accelerated MIC testing
      • Bacterial broad spectrum screen
      • Fungal broad spectrum screen
      • Neisseria gonorrhoeae - MDR and susceptible strains
    • Time-kill analysis to identify bactericidal properties
    • Combination testing to determine synergistic, indifferent or antagonistic effects
    • Resistance analysis to determine the rate at which organisms develop a non-susceptible phenotype
    • Membrane lysis - bacteria and red blood cells
    • Clostridium difficile toxin - cytotoxicity and toxin neutralization
    • >270 pathogens, including:
      • Anaerobic bacteria: C. difficile, P. vulgaris
      • Fungi: C. albicans, A. fumigatus
      • Gram-negative bacteria: A. baumannii, E. coli, K. pneumoniae, N. gonorrhoeae, P. aeruginosa
      • Gram-positive bacteria: E. faecalis, S. aureus, S. epidermidis, S. pneumoniae, S. pyogenes
  • Companion in vivo services for preclinical anti-microbial assessment